Posted 11/18/2019 10:31 PM (GMT -6)
I read the link you posted SS, VERY interesting....It's interesting to note that Endocyte / Novartis is a major funder and contributor of these Australian trials and studies.. Australian doctors have been treating various types of cancer with Lu-177 compounds since 2015 ! By now, the safety issues must be pretty well resolved..The Nuclear Production Labs needed to produce and distribute these radio-pharmaceuticals are already in place. !
Those lucky few who have been treated with Lu-177 / PSMA 617 and got a good response to it (about 65% get a good response) have seen their mortality extended by as much as 40 months..This is better than any of the other drugs and treatments used to treat advanced, stage 4, prostate cancer patients..The next big question, after it's approved, how much will Novartis charge for it ?